Key facts
- It has raised $130K; the latest was Later Stage VC ($100K) in Mar 2026.
- Notable investors include Launch Tennessee, Biolocity, Georgia Research Alliance, U.S. Department of Health and Human Services, ZeroTo510.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for CorAmi
- ·The full record, as it builds
Funding rounds
No funding rounds for CorAmi are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CorAmi
Developer of a drug delivery platform intended for the delivery of cardiac therapeutics. The company's platform focuses on cardiac applications and combines medical devices and therapeutic hydrogels, resulting in a therapeutic intervention for atrial fibrillation and enabling healthcare professionals to access new treatment strategies for cardiac diseases.
- Sector
- Healthcare
- HQ
- Atlanta, GA, United States
- Founded
- 2016
- Website
- coramibio.com/
- Ownership
- Privately Held (backing)
CorAmi doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CorAmi shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CorAmi in its N-PORT filings yet. We sweep new filings monthly.